Promising effects of high-intensity focused ultrasound combined with eribulin and sintilimab in a patient with advanced leiomyosarcoma: a case report and literature review - Report - MDSpire
Advertisement
Promising effects of high-intensity focused ultrasound combined with eribulin and sintilimab in a patient with advanced leiomyosarcoma: a case report and literature review
Clinical Report: Efficacy of High-Intensity Focused Ultrasound in Combination with Eribulin and Sintilimab for Advanced Leiomyosarcoma
Background
Leiomyosarcoma (LMS) is a challenging malignancy with a high risk of recurrence and metastasis, and the prognosis for advanced cases is particularly poor due to limited treatment options. Standard therapies often fail, necessitating exploration of novel combinations.
Data Highlights
No numerical data or trial data presented in the article.
Key Findings
A 49-year-old male with advanced bladder LMS achieved disease stabilization after two cycles of eribulin and sintilimab.
Subsequent addition of HIFU resulted in a partial response, with significant tumor reduction observed.
The partial response was maintained for 7.2 months with continued eribulin and sintilimab treatment.
The patient had a progression-free survival of 7.2 months and an overall survival of 57 months since diagnosis.
Clinical Implications
The integration of HIFU with systemic therapies like eribulin and sintilimab may offer a new treatment avenue for patients with advanced LMS.
Conclusion
This case presents findings on the combination of local and systemic therapies in the management of advanced LMS.
